Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 24Uterine Cervical Neoplasms 18Fallopian Tube Neoplasms 15Endometrial Neoplasms 13Neoplasm Metastasis 9Breast Neoplasms 9Pancreatic Neoplasms 8Uterine Cervical Dysplasia 6Melanoma 6Colorectal Neoplasms 6Prostatic Neoplasms 5Stomach Neoplasms 4Precancerous Conditions 4Carcinosarcoma 4Carcinoma, Renal Cell 4Vulvar Neoplasms 3Uterine Neoplasms 3Urinary Bladder Neoplasms 3Triple Negative Breast Neoplasms 3Squamous Intraepithelial Lesions 3Sarcoma 3Salivary Gland Neoplasms 3Neoplasms 3Carcinoma, Ovarian Epithelial 3Carcinoma, Non-Small-Cell Lung 3Anus Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Skin Neoplasms 2Rectal Neoplasms 2Papillomavirus Infections 2

Interventions

Transcriptome 1Taxes 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Paclitaxel 1Microarray Analysis 1Immunohistochemistry 1Gene Expression Profiling 1Carboplatin 1Blotting, Western 1Biopsy 13-aminopyridine-2-carboxaldehyde thiosemicarbazone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Serous Adenocarcinoma × Biopsy × Gynecologic × Clear all
NCT04494113 2026-05-13

Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy

National Cancer Institute (NCI)

Phase EARLY_PHASE1 Active not recruiting
12 enrolled
Gynecologic

Endometrial Serous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡